Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

Author：                          

Publisher： Spandidos Publications

ISSN： 1792-0981

Source： Experimental and Therapeutic Medicine, Vol.3, Iss.2, 2012-01, pp. : 207-213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report

By Kamila Wojas-Krawczyk   Michał Skroński   Paweł Krawczyk   Paulina Jaguś   Tomasz Kucharczyk   Bożena Jarosz   Radosław Mlak   Justyna Szumiło   Marek Sawicki   Trojanowski Tomasz   Janusz Milanowski   Joanna Chorostowska-Wynimko  

Clinical and Experimental Metastasis, Vol. 30, Iss. 8, 2013-12 ,pp. : 1063-1071

Springer Publishing Company

Access to resources Recommend Favorite

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

By Sun Jong-Mu   Won Young-Woong   Kim Seung   Kim Jung   Choi Yoon-La   Lee Jeeyun   Park Yeon   Ahn Jin   Park Keunchil   Ahn Myung-Ju  

Journal of Cancer Research and Clinical Oncology, Vol. 137, Iss. 4, 2011-04 ,pp. : 687-694

Springer Publishing Company

Access to resources Recommend Favorite

High efficacy of gefitinib in the treatment of EGFR mutationpositive advanced nonsmall cell lung adenocarcinoma: A case report

By    

Oncology Letters, Vol. 8, Iss. 3, 2014-01 ,pp. : 1320-1322

Spandidos Publications

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite

Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas

By Sonobe Makoto   Kobayashi Masashi   Ishikawa Masashi   Kikuchi Ryutaro   Nakayama Ei   Takahashi Tsuyoshi   Menju Toshi   Takenaka Kazumasa   Miyahara Ryo   Huang Cheng-Long   Okubo Kenichi   Bando Toru   Date Hiroshi  

Annals of Surgical Oncology, Vol. 19, Iss. 3, 2012-07 ,pp. : 347-354

Springer Publishing Company

Access to resources Recommend Favorite